Nowak Jerzy Z, Kuba Katarzyna
Department of Biogenic Amines, Polish Academy of Sciences, Lodz.
J Mol Neurosci. 2002 Feb-Apr;18(1-2):47-52. doi: 10.1385/JMN:18:1-2:47.
Pituitary adenylate cyclase-activating polypeptide (PACAP; 0.001-1 microM) and vasoactive intestinal peptide (VIP; 0.01-1 microM) produced a concentration-dependent stimulation of cyclic AMP (cAMP) formation in rat cerebral cortical slices prelabeled with [3H]adenine. The effects of PACAP38 and PACAP27 were similar, and more efficacious (at 0.1 and 1 microM) than those of VIP. Adrenaline and noradrenaline (each at 100 microM) also stimulated cAMP formation, with the latter compound being more effective. Combination of PACAP38, PACAP27 (each at 0.1 microM) and VIP (1 microM) with adrenaline or noradrenaline resulted in most cases in additive effects, with some supraadditive (PACAP27 plus adrenaline) or subadditive (PACAP38 or VIP plus noradrenaline) fluctuations. In contrast, combination of each of the three peptides with 3 microM forskolin resulted in synergistic effects. These results indicate that in rat cerebral cortex there is no synergism between PACAP or VIP with noradrenaline or adrenaline; however, based on the forskolin data, it seems likely that synergistic effects may take place with VIP or PACAP and other cAMP-stimulating neuroregulators.
垂体腺苷酸环化酶激活多肽(PACAP;0.001 - 1微摩尔)和血管活性肠肽(VIP;0.01 - 1微摩尔)对预先用[3H]腺嘌呤标记的大鼠大脑皮质切片中的环磷酸腺苷(cAMP)生成产生浓度依赖性刺激作用。PACAP38和PACAP27的作用相似,且在0.1和1微摩尔时比VIP更有效。肾上腺素和去甲肾上腺素(均为100微摩尔)也刺激cAMP生成,后一种化合物更有效。PACAP38、PACAP27(均为0.1微摩尔)和VIP(1微摩尔)与肾上腺素或去甲肾上腺素联合使用,在大多数情况下产生相加效应,伴有一些超相加(PACAP27加肾上腺素)或次相加(PACAP38或VIP加去甲肾上腺素)波动。相反,这三种肽中的每一种与3微摩尔福斯高林联合使用均产生协同效应。这些结果表明,在大鼠大脑皮质中,PACAP或VIP与去甲肾上腺素或肾上腺素之间不存在协同作用;然而,根据福斯高林的数据,VIP或PACAP与其他cAMP刺激神经调节剂之间似乎可能发生协同效应。